Liver cancer: From molecular pathogenesis to new therapies. Summary of the EASL single topic conference

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 296-304

  Dufour, Jean François ^a   Johnson, Philip ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cancer; Liver transplantation; Local therapy; Multi kinase inhibitor

Indexed keywords

ALCOHOL; ALPHA INTERFERON; BEVACIZUMAB; BRIVANIB; CALCINEURIN INHIBITOR; DOXORUBICIN; ERLOTINIB; FLICE INHIBITORY PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; INTERFERON; IRINOTECAN; LAMIVUDINE; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TRANSCRIPTOME; TUMOR MARKER; VIRUS DNA;

ADVANCED CANCER; ANGIOGENESIS; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHEMOEMBOLIZATION; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG ELUTING BEAD; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERCUTANEOUS ETHANOL INJECTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RISK FACTOR; SURVIVAL TIME; ULTRASOUND;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; EUROPE; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; SOCIETIES, SCIENTIFIC;

EID: 75349110931     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.010     Document Type: Conference Paper

References (117)

1. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
3. Ribes J., Cleries R., Esteban L., Moreno V., and Bosch F.X. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 49 (2008) 233-242
4. Bosetti C., Levi F., Boffetta P., Lucchini F., Negri E., and La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48 (2008) 137-145
5. Smith J.B., and Blumberg B.S. Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma. Lancet 2 (1969) 953
6. Beasley R.P., Hwang L.Y., Lin C.C., and Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2 (1981) 1129-1133
7. Chang M.H., Chen T.H., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 11 (2005) 7953-7957
8. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis Be antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
9. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
10. Yang H.I., Yeh S.H., Chen P.J., Iloeje U.H., Jen C.L., Su J., et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 1134-1143
11. Turner P.C., Sylla A., Gong Y.Y., Diallo M.S., Sutcliffe A.E., Hall A.J., et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 365 (2005) 1950-1956
12. Murakami Y., Saigo K., Takashima H., Minami M., Okanoue T., Brechot C., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54 (2005) 1162-1168
13. Cougot D., Wu Y., Cairo S., Caramel J., Renard C.A., Levy L., et al. The hepatitis B virus × protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 282 (2007) 4277-4287
14. Bouchard M.J., Wang L.H., and Schneider R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 294 (2001) 2376-2378
15. Bouchard M.J., Wang L., and Schneider R.J. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 80 (2006) 4406-4414
16. Kim K.H., and Seong B.L. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 22 (2003) 2104-2116
17. Moon E.J., Jeong C.H., Jeong J.W., Kim K.R., Yu D.Y., Murakami S., et al. Hepatitis B virus × protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 18 (2004) 382-384
18. Pollicino T., Belloni L., Raffa G., Pediconi N., Squadrito G., Raimondo G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130 (2006) 823-837
19. Kwon J.A., and Rho H.M. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells. Biol Chem 384 (2003) 203-212
20. Du J., Liang X., Liu Y., Qu Z., Gao L., Han L., et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 16 (2009) 219-229
21. Bruno S., Crosignani A., Maisonneuve P., Rossi S., Silini E., and Mondelli M.U. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46 (2007) 1350-1356
22. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61 (2001) 4365-4370
23. Street A., Macdonald A., Crowder K., and Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 279 (2004) 12232-12241
24. Street A., Macdonald A., McCormick C., and Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 79 (2005) 5006-5016
25. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., and Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
26. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
27. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49 (2009) 851-859
28. Calvisi D.F., Ladu S., Gorden A., Farina M., Lee J.S., Conner E.A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117 (2007) 2713-2722
29. Matsuda Y., Ichida T., Matsuzawa J., Sugimura K., and Asakura H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116 (1999) 394-400
30. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
31. Laurent-Puig P., Legoix P., Bluteau O., Belghiti J., Franco D., Binot F., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 (2001) 1763-1773
32. Iizuka N., Oka M., Yamada-Okabe H., Nishida M., Maeda Y., Mori N., et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361 (2003) 923-929
33. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9 (2003) 416-423
34. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004) 667-676
35. Lee J.S., and Thorgeirsson S.S. Comparative and integrative functional genomics of HCC. Oncogene 25 (2006) 3801-3809
36. Chiang D.Y., Villanueva A., Hoshida Y., Peix J., Newell P., Minguez B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008) 6779-6788
37. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47 (2008) 1955-1963
38. Llovet J.M., and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 (2008) 1312-1327
39. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 (2006) 99-111
40. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
41. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
42. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
43. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34
44. Faivre S., Raymond E., Boucher E., Douillard J., Lim H.Y., Kim J.S., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10 (2009) 794-800
45. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27 (2009) 3027-3035
46. Semela D., and Dufour J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 41 (2004) 864-880
47. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., and Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100 (2009) 1385-1392
48. Thomas M.B., Morris J.S., Chadha R., Iwasaki M., Kaur H., Lin E., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27 (2009) 843-850
49. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. MTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
50. Sieghart W., Fuereder T., Schmid K., Cejka D., Werzowa J., Wrba F., et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83 (2007) 425-432
51. Baba H.A., Wohlschlaeger J., Cicinnati V.R., Hilgard P., Lang H., Sotiropoulos G.C., et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 29 (2009) 399-405
52. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48 (2008) 83-90
53. Semela D., Piguet A.C., Kolev M., Schmitter K., Hlushchuk R., Djonov V., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46 (2007) 840-848
54. Piguet A.C., Semela D., Keogh A., Wilkens L., Stroka D., Stoupis C., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49 (2008) 78-87
55. Toso C., Meeberg G.A., Bigam D.L., Oberholzer J., Shapiro A.M., Gutfreund K., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83 (2007) 1162-1168
56. Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Campsen J., Skibba A., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14 (2008) 633-638
57. Dufour J.F., Huber O., Kozma S.C., Lu X., and Toftgard R. Tumour suppressors in liver carcinogenesis. J Hepatol 47 (2007) 860-867
58. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
59. Taylor J.M., Braun T.M., and Li Z. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design. Clin Trials 3 (2006) 335-348
60. Johnson P.J., and Billingham L.J. Clinical trial design in hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19 (2005) 119-127
61. Koda M., Murawaki Y., Mitsuda A., Ohyama K., Horie Y., Suou T., et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 88 (2000) 529-537
62. Khan K.N., Yatsuhashi H., Yamasaki K., Yamasaki M., Inoue O., Koga M., et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 32 (2000) 269-278
63. Sasaki A., Kai S., Iwashita Y., Hirano S., Ohta M., and Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 103 (2005) 299-306
64. Lencioni R.A., Allgaier H.P., Cioni D., Olschewski M., Deibert P., Crocetti L., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
65. Cho Y.K., Kim J.K., Kim M.Y., Rhim H., and Han J.K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49 (2009) 453-459
66. Chen M.S., Li J.Q., Zheng Y., Guo R.P., Liang H.H., Zhang Y.Q., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 (2006) 321-328
67. Livraghi T., Meloni F., Di Stasi M., Rolle E., Solbiati L., Tinelli C., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 47 (2008) 82-89
68. Lu D.S., Yu N.C., Raman S.S., Lassman C., Tong M.J., Britten C., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41 (2005) 1130-1137
69. Lencioni R., Crocetti L., Petruzzi P., Vignali C., Bozzi E., Della Pina C., et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 49 (2008) 217-222
70. Lencioni R., and Llovet J.M. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?. J Hepatol 43 (2005) 377-380
71. Marelli L., Stigliano R., Triantos C., Senzolo M., Cholongitas E., Davies N., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 (2007) 6-25
72. Camma C., Schepis F., Orlando A., Albanese M., Shahied L., Trevisani F., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
73. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
74. Varela M., Real M.I., Burrel M., Forner A., Sala M., Brunet M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (2007) 474-481
75. Malagari K., Chatzimichael K., Alexopoulou E., Kelekis A., Hall B., Dourakis S., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31 (2008) 269-280
76. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 792-800
77. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47 (2008) 71-81
78. Strebel B.M., and Dufour J.F. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 8 (2008) 1743-1749
79. Yoo H.Y., Patt C.H., Geschwind J.F., and Thuluvath P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21 (2003) 4329-4335
80. Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10 (2009) 35-43
81. Freeman R.B., Edwards E.B., and Harper A.M. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 6 (2006) 1416-1421
82. Piscaglia F., Camaggi V., Ravaioli M., Grazi G.L., Zanello M., Leoni S., et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 13 (2007) 857-866
83. Yamashita T., Forgues M., Wang W., Kim J.W., Ye Q., Jia H., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 (2008) 1451-1461
84. Faria L.C., Gigou M., Roque-Afonso A.M., Sebagh M., Roche B., Fallot G., et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134 (2008) 1890-1899 quiz 2155
85. Soderdahl G., Backman L., Isoniemi H., Cahlin C., Hockerstedt K., Broome U., et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 19 (2006) 288-294
86. Maddala Y.K., Stadheim L., Andrews J.C., Burgart L.J., Rosen C.B., Kremers W.K., et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10 (2004) 449-455
87. Millonig G., Graziadei I.W., Freund M.C., Jaschke W., Stadlmann S., Ladurner R., et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 13 (2007) 272-279
88. Mazzaferro V., Battiston C., Perrone S., Pulvirenti A., Regalia E., Romito R., et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240 (2004) 900-909
89. Aloia T.A., Adam R., Samuel D., Azoulay D., and Castaing D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 11 (2007) 1328-1332
90. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
91. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
92. Kim D.Y., Han K.H., Ahn S.H., Paik Y.H., Lee K.S., and Chon C.Y. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology 46 (2007) 403A
93. Hagiwara S., Kudo M., Kawasaki T., Nagashima M., Minami Y., Chung H., et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 41 (2006) 1214-1219
94. Nakamura S., Nouso K., Sakaguchi K., Ito Y.M., Ohashi Y., Kobayashi Y., et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101 (2006) 2038-2043
95. Shirabe K., Itoh S., Yoshizumi T., Soejima Y., Taketomi A., Aishima S., et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma - with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 95 (2007) 235-240
96. Carr B.I., Kanke F., Wise M., and Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52 (2007) 776-782
97. Liu X.E., Desmyter L., Gao C.F., Laroy W., Dewaele S., Vanhooren V., et al. N-Glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46 (2007) 1426-1435
98. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 (2003) 89-97
99. Marrero J.A., Romano P.R., Nikolaeva O., Steel L., Mehta A., Fimmel C.J., et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43 (2005) 1007-1012
100. Chan A.C., Poon R.T., Ng K.K., Lo C.M., Fan S.T., and Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 247 (2008) 666-673
101. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol 4 (2006) 1170-1176
102. Yuen M.F., Cheng C.C., Lauder I.J., Lam S.K., Ooi C.G., and Lai C.L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31 (2000) 330-335
103. Bolondi L., Sofia S., Siringo S., Gaiani S., Casali A., Zironi G., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48 (2001) 251-259
104. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G., Romeo R., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004) 1005-1014
105. Forner A., Vilana R., Ayuso C., Bianchi L., Sole M., Ayuso J.R., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47 (2008) 97-104
106. Durand F., Regimbeau J.M., Belghiti J., Sauvanet A., Vilgrain V., Terris B., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35 (2001) 254-258
107. Choi D., Mitchell D.G., Verma S.K., Bergin D., Navarro V.J., Malliah A.B., et al. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology 244 (2007) 776-783
108. Saborido B.P., Diaz J.C., de Los Galanes S.J., Segurola C.L., de Usera M.A., Garrido M.D., et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma?. Transplant Proc 37 (2005) 3874-3877
109. Camma C., Giunta M., Andreone P., and Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34 (2001) 593-602
110. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007) 579-587
111. Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., Zeuzem S., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007) 677-684
112. Lok A.S., Seeff L.B., Morgan T.R., di Bisceglie A.M., Sterling R.K., Curto T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009) 138-148
113. Mazzaferro V., Romito R., Schiavo M., Mariani L., Camerini T., Bhoori S., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44 (2006) 1543-1554
114. Lin S.M., Yu M.L., Lee C.M., Chien R.N., Sheen I.S., Chu C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
115. Matsumoto A., Tanaka E., Rokuhara A., Kiyosawa K., Kumada H., Omata M., et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 32 (2005) 173-184
116. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
117. Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40 (2004) 883-891